- Home
- LCID vs EXAS Comparison
LCID vs EXAS Comparison
Compare LCID & EXAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LCID
- EXAS
- Stock Information
- Founded
- LCID 2007
- EXAS 1995
- Country
- LCID United States
- EXAS United States
- Employees
- LCID N/A
- EXAS N/A
- Industry
- LCID Auto Manufacturing
- EXAS Medical Specialities
- Sector
- LCID Consumer Discretionary
- EXAS Health Care
- Exchange
- LCID Nasdaq
- EXAS Nasdaq
- Market Cap
- LCID 9.0B
- EXAS 8.8B
- IPO Year
- LCID N/A
- EXAS N/A
- Fundamental
- Price
- LCID $2.41
- EXAS $43.28
- Analyst Decision
- LCID Hold
- EXAS Strong Buy
- Analyst Count
- LCID 10
- EXAS 18
- Target Price
- LCID $2.99
- EXAS $70.59
- AVG Volume (30 Days)
- LCID 97.1M
- EXAS 2.0M
- Earning Date
- LCID 05-05-2025
- EXAS 05-07-2025
- Dividend Yield
- LCID N/A
- EXAS N/A
- EPS Growth
- LCID N/A
- EXAS N/A
- EPS
- LCID N/A
- EXAS N/A
- Revenue
- LCID $807,832,000.00
- EXAS $2,758,867,000.00
- Revenue This Year
- LCID $86.18
- EXAS $13.02
- Revenue Next Year
- LCID $93.75
- EXAS $13.02
- P/E Ratio
- LCID N/A
- EXAS N/A
- Revenue Growth
- LCID 35.71
- EXAS 10.37
- 52 Week Low
- LCID $1.93
- EXAS $40.62
- 52 Week High
- LCID $4.43
- EXAS $79.62
- Technical
- Relative Strength Index (RSI)
- LCID 50.22
- EXAS 37.18
- Support Level
- LCID $2.25
- EXAS $44.00
- Resistance Level
- LCID $2.52
- EXAS $47.23
- Average True Range (ATR)
- LCID 0.15
- EXAS 1.57
- MACD
- LCID 0.04
- EXAS 0.09
- Stochastic Oscillator
- LCID 71.43
- EXAS 23.60
About LCID Lucid Group Inc.
Lucid Group Inc is a technology and automotive company. It develops the next generation of electric vehicle (EV) technologies. It is a vertically integrated company that designs, engineers, and builds electric vehicles, EV powertrains, and battery systems in-house using our own equipment and factory.
About EXAS Exact Sciences Corporation
Exact Sciences Corporation, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test, a noninvasive stool-based DNA test, is a pre-cancer screening test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is developing liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening, too.